4D-150
Asset
Intravitreal gene therapy expresses aflibercept and a VEGFC-targeting microRNA to suppress vascular leakage and abnormal blood vessel growth.
- Stage
- Phase 3
- Modality
- Gene therapy
- Target
- VEGFA
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Diabetic macular edema
Phase 3, Recruiting, NCT07867080, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials1
- Evidence for its targets4
- Competitors10
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.